Actively Recruiting
Neurocutaneous Melanocytosis Registry
Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-09-30
100
Participants Needed
2
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).
CONDITIONS
Official Title
Neurocutaneous Melanocytosis Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with large cutaneous melanocytic nevi (LCMN), defined as a dark-colored skin patch present at birth
- LCMN may be located anywhere on the skin and can include satellite lesions or excess hair (hypertrichosis)
- Patients without skin involvement must have histologically or radiographically confirmed central nervous system melanocytosis
- Patients of any age at diagnosis
- Signed informed consent by the patient or parent/legal guardian
- Deceased patients can be included if the parent/legal guardian is contacted at least 6 months after the child's death and not on the child's birthday or death anniversary
You will not qualify if you...
- Informed consent has not been provided
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Boston Children's Hospital (Data Analysis Only)
Boston, Massachusetts, United States, 02115
Not Yet Recruiting
2
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
Research Team
Y
Yasmin Khakoo, MD
CONTACT
S
Sofia Haque, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here